storage comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-07. Numbers and descriptions here follow the published literature rather than marketing material.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
== Bibliography == Greenwood, Norman N.; Earnshaw, Alan (1997). Chemistry of the Elements (2nd ed.). Butterworth–Heinemann. ISBN 978-0080379418. Haire, Richard G. (2006). "Einsteinium". In Morss, Lester R.; Edelstein, Norman M.; Fuger, Jean (eds.). The Chemistry of the Actinide and Transactinide Elements (PDF). Vol. 3 (3rd ed.). Dordrecht, the Netherlands: Springer. pp. 1577–1620. doi:10.1007/1-4020-3598-5_12. ISBN 978-1-4020-3555-5. Archived from the original (PDF) on 2010-07-17. Holleman, Arnold F. & Wiberg, Nils (2007). Textbook of Inorganic Chemistry (102nd ed.). Berlin: de Gruyter. ISBN 978-3-11-017770-1. Seaborg, G.T., ed. (23 January 1978). Proceedings of the Symposium Commemorating the 25th Anniversary of Elements 99 and 100 (PDF). Report LBL-7701.
In the summer semester of 2013, he was a visiting professor for Islamic intellectual history at the Goethe University Frankfurt. In the spring of 2014, he taught German literature as Max Kade visiting professor at Dartmouth College in New Hampshire. From 2017 to 2020, Kermani taught creative writing as a visiting professor at the Academy of Media Arts Cologne. On 22 October 2023, Kermani read texts on Beethoven's Ninth Symphony at the Berlin Philharmonic during a concert by the German Symphony Orchestra Berlin under Robin Ticciati.
Other tools include DocFinder at docfinder.docboard.org and certificationmatters.org from the American Board of Medical Specialties. In some cases more information is available from a mailed or walk-in request than the internet; for example, the Medical Board of California removes dismissed accusations from website profiles, but these are still available from a written or walk-in request, or a lookup in a separate database. The trend to disclosure is controversial and generate significant public debate, particularly about opening up the National Practitioner Data Bank. In 1996, Massachusetts became the first state to require detailed disclosure of malpractice claims.
Triisopropyl silane (TIPS) is an organosilicon compound with the formula (i-Pr)3SiH (i-Pr = isopropyl). This colorless liquid is used as a scavenger in peptide synthesis. It can also act as a mild reducing agent. In peptide synthesis, TIPS is used as a scavenger for peptide groups being removed from the peptide sequence at the global deprotection. TIPS is able to scavenge carbocations formed in the deprotection of a peptide as it can act as a hydride donor in acidic conditions. Silanes may be preferred as scavengers in place of sulfur-based scavengers.
=== Tyrannosaurus imperator and Tyrannosaurus regina === In a 2022 study, Gregory S. Paul and colleagues argued that Tyrannosaurus rex, as traditionally understood, actually represents three species: the type species Tyrannosaurus rex, and two previously unrecognized species: T. imperator (meaning "tyrant lizard emperor") and T. regina (meaning "tyrant lizard queen"). The holotype of the former (T. imperator) is the Sue specimen, and the holotype of the latter (T. regina) is Wankel rex. The division into multiple species was primarily based on the high degree of variation in the proportions and robusticity of the femur (and other skeletal elements) across T. rex specimens. Presumed robust and gracile morphotypes and the number of small incisiform teeth in the dentary were also used as a line of evidence. Paul and colleagues categorized the species as follows: T. rex demonstrates robust anatomy, a moderate ratio of femur length vs circumference, and the possession of a singular slender incisiform dentary tooth, T. imperator is robust with a small femur length to circumference ratio and two of the slender teeth, and T. regina is more gracile with a high femur ratio and one of the slender teeth. However, several leading paleontologists, including Stephen Brusatte, Thomas Carr, Thomas Holtz, David Hone, Jingmai O'Connor, and Lindsay Zanno, criticized the study or expressed skepticism of its conclusions.
Sources: en.wikipedia.org
== External links == GeneReviews/NCBI/NIH/UW entry on Cystinosis Human CTNS genome location and CTNS gene details page in the UCSC Genome Browser. Genetics Home Reference page on CTNS. Genetic Testing Registry.
In 1783, a series of earthquakes across Calabria caused around 50,000 deaths and damaged property. Many of the buildings were rebuilt thereafter. In 1733, after the outbreak of the War of Polish Succession, the Spanish Bourbons, allies of France against Austria, decided to attack Naples and secure that kingdom for Charles VII. Charles, who entered Naples in 1734, defeated the Austrian troops at the Battle of Bitonto, securing control of the kingdom, despite pockets of resistance, including Reggio Calabria, which fell on 20 June 1734. For ten years, however, the young Bourbon monarchy had to cope with the intrigues of the Austrian party present in Naples. This was particularly strong in Calabria, where the Duke of Verzino promised the Austrians that he could arm 12,000 rebels for their cause of reconquest during the War of Austrian Succession. The Duke had already armed an infantry regiment against the Infante in 1734. But after the Battle of Velletri in 1744, in which Charles VII repelled an Austrian invasion, the Austrian party disappeared, decimated by the Bourbon trials and inquisitions. Charles VII of Naples ascension aroused enthusiasm throughout the Mezzogiorno, as the population hoped that the resources of the Kingdom of Naples would be used for the development of state and social structures. Sicily, too, united politically with southern Italy; this was an advantage for Calabria, which moved to the center of the state structure. This was seen in Charles' popular journey in 1735, while on his way to Palermo to be crowned King of Sicily.
== Business model == Juniper is identified as part of a vertically integrated healthcare model in the Australian telehealth sector. Its clinical consultations, prescribing and medication delivery are offered within a single online platform. This model has drawn regulatory attention over advertising practices and conflicts between commercial incentives and clinical decision-making. Regulators emphasise that prescribing decisions remain the responsibility of individual clinicians.
=== Prepared solutions === Prepared solutions generally consist of water and electrolytes; glucose, amino acids, and lipids; essential vitamins, minerals and trace elements are added or given separately. Previously lipid emulsions were given separately but it is becoming more common for a "three-in-one" solution of glucose, proteins, and lipids to be administered.
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.